At a glance
ClinicalIndex Comparison Record- ✓Stage IV invasive breast cancer with unequivocal evidence of metastasis
- ✓HR-positive, HER2-negative breast cancer (ER >1% and/or PR >1%)
- ✓At least two prior lines of hormonal therapy OR appropriate candidate for chemotherapy
- ✓Up to 2 prior lines of metastatic chemotherapy allowed
- ✕Prior treatment with eribulin mesylate or any anti-PD-1/PD-L1/PD-L2 agent
- ✕Unresolved chemotherapy or radiation-related toxicities >Grade 1 (except stable neuropathy ≤Grade 2 and alopecia)
- ✕Known untreated, symptomatic, or uncontrolled brain metastases
- ✕Uncontrolled intercurrent illness (hypertension, cardiac arrhythmia, heart failure NYHA III-IV, MI within 6 months, uncontrolled diabetes)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Study Of Eribulin Mesylate With Or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
In Brief
A Phase 2 clinical trial evaluating Eribulin Mesylate and Pembrolizumab for Breast Cancer. Completed, enrolled 90 participants across 3 sites.
Detailed Summary
This research study is exploring chemotherapy in combination with immunotherapy (a therapy that uses the body's own immune system to control cancer) as a possible treatment for metastatic hormone receptor positive breast cancer.
Study Details
Timeline
Interventions
Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.